The HRH1 Knockout NCI-H1703 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal cell population derived from the NCI-H1703 human lung squamous cell carcinoma cell line, in which the HRH1 gene has been disrupted to establish a loss-of-function model. This polyclonal knockout pool contains a heterogeneous mixture of cells with targeted gene disruption, providing a robust tool for studying the functional consequences of HRH1 ablation without the limitations of single-cell clonal selection. The use of polyclonal cells mitigates clonal artifacts and ensures representation of the full editing spectrum, making it suitable for population-level analyses of histamine receptor signaling in a cancer context.
The parental NCI-H1703 cell line originates from a lymph node metastasis of a lung squamous cell carcinoma resected from a 54-year-old male smoker. It is a widely characterized model for non-small cell lung cancer (NSCLC), exhibiting properties typical of aggressive squamous cell carcinomas, including rapid proliferation and invasive capacity. NCI-H1703 cells retain key genomic and signaling features of the original tumor, enabling relevant investigations of oncogenic pathways in a metastatic lung cancer background. This well-annotated cell line provides a physiologically meaningful host for gene-editing studies.
HRH1 encodes the histamine H1 receptor, a proinflammatory G protein-coupled receptor that signals primarily through the Gq/11 alpha subunit. Upon histamine binding, HRH1 activates phospholipase C beta (PLCB), leading to the hydrolysis of phosphatidylinositol 4,5-bisphosphate into inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers calcium release from intracellular stores, while DAG activates protein kinase C (PKC). These events converge on downstream cascades such as the MAPK/ERK pathway (including ERK1/2, encoded by MAPK3/MAPK1) and the NF-kB pathway (involving RELA/p65). The receptor’s activity is modulated by GPCR kinases (GRK2, GRK5) and beta-arrestins (ARRB1, ARRB2), which regulate desensitization and internalization. In cancer cells, HRH1 signaling promotes the expression of matrix metalloproteinases and vascular endothelial growth factor, contributing to invasiveness and angiogenesis.
In the NCI-H1703 NSCLC model, HRH1 mediates histamine-driven proliferation, migration, and invasion, positioning it as a potential therapeutic target. Disruption of HRH1 via CRISPR/Cas9 enables dissection of its oncogenic contribution against the backdrop of lung squamous cell carcinoma. This knockout polyclonal population allows researchers to assess how loss of histamine signaling affects tumor cell behavior, calcium dynamics, and downstream transcriptional programs. The model is particularly relevant for studying the intersection of chronic inflammation and cancer progression, as HRH1 links the proinflammatory microenvironment to malignant phenotypes.
Typical research applications include examining the role of HRH1 in NSCLC cell motility through transwell migration assays, evaluating changes in intracellular calcium fluxes via fluorescence imaging, and quantifying activation of ERK and NF-kB using phospho-ERK ELISA or luciferase-based reporter assays. The polyclonal cells are also suitable for drug screening aimed at identifying antihistamines or inverse agonists with anticancer activity, and for in vivo xenograft tumor studies to monitor metastasis and growth. Standard molecular analyses such as Western blotting and RT-qPCR further enable validation of downstream targets like c-Fos and VEGF. For additional product information or technical support, please contact Ascent Research.
